Skip to main content
NXTC
NASDAQ Life Sciences

NextCure Sets Dec 9 Vote on Avere Merger; Legacy Holders Keep Just 0.99%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$6.31
Mkt Cap
$28.883M
52W Low
$1.55
52W High
$15.74
52W Position info
307% above low
Off High info
60% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

NXTC has more than doubled off its 52-week low of $1.55 on light trading volume (0.1× avg).

Summary

NextCure's amended S-4 sets a December 9, 2026 shareholder vote on the Avere reverse merger, under which current NextCure holders would retain only about 0.99% of the combined company. A no-vote likely means liquidation with little left for stockholders.


Key Events · M&A and Partnerships · NXTC

  • Special Meeting Set for December 9

    NextCure stockholders vote December 9, 2026 on issuing shares to Avere holders, the change of control, raising authorized shares from 100,000,000 to 800,000,000, and the Texas re-domiciliation. The record date is November 3, 2026.

  • Legacy Holders Keep 0.99%

    At the estimated 6.9730 exchange ratio, pre-merger NextCure holders would own about 0.99% of the combined company on a fully diluted basis, Avere holders about 39.69%, and Avere pre-closing financing investors about 59.32%.

  • Avere Financing Now $820 Million

    The Avere pre-closing financing totals $820.0 million: $320.0 million at $9.8093 per share plus a $500.0 million amendment at $27.6621 per share. About $266.0 million is paid by cancelling convertible notes rather than new cash.

  • Liquidation Would Leave Little

    NextCure had about $20.1 million of cash at June 30, 2026 against estimated wind-down costs of about $19.2 million, so its own analysis shows no meaningful near-term distribution if the merger fails.


Analysis · NXTC · Life Sciences

The proxy that decides whether NextCure survives as a company is now in front of shareholders. Should the merger close, existing NextCure holders keep roughly 0.99% of the combined company, while Avere's pre-closing investors take about 59.32% — in effect, the public listing is being handed to Avere's oral IL-23 program, AVR-001. A no vote, by contrast, could mean liquidation: NextCure's own analysis shows wind-down costs of about $19.2 million against roughly $20.1 million of cash, leaving little or nothing for stockholders. The vote is set for December 9, 2026, and every required proposal must pass or the deal dies.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NXTC was trading at $6.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.9M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NXTC - Latest Insights

NXTC
Nov 10, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.78
Real-time Price: $6.68 info
Change: +$0.900 (+16%) info
Market Cap: $30.588M info
NXTC
Nov 10, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $6.68 info
Change: +$0.900 (+16%) info
Market Cap: $30.588M info
NXTC
Nov 10, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $6.68 info
Change: +$0.900 (+16%) info
Market Cap: $30.588M info
NXTC
Sep 30, 2026, 7:36 PM EDT
Filing Type: S-4/A
Importance Score:
9
Price at Filing: $5.01
Real-time Price: $6.68 info
Change: +$1.67 (+33%) info
Market Cap: $30.588M info
NXTC
Sep 25, 2026, 4:12 PM EDT
Filing Type: 425
Importance Score:
8
Price at Filing: $5.08
Real-time Price: $6.68 info
Change: +$1.60 (+31%) info
Market Cap: $30.588M info